TFX Stock Recent News
TFX LATEST HEADLINES
TFX gains 2.9% after acquiring BIOTRONIK's vascular unit, boosting its cath lab presence and innovation pipeline.
WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex's portfolio of interventional access products, driving an enhanced global presence in the cath lab. The Vascular Intervention business will also establish Teleflex's global footprint in the fast-growing peripheral intervention market, and provide a channel for Teleflex products that currently have a peripheral indication.
WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey.
Timed with National Men's Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men 1 —and encourages them to take control of their health.
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public.
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / WHY: New York, N.Y., May 21, 2025.
NEW YORK , May 20, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public. So What: If you purchased Teleflex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public.
Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program Highlights Accomplishments and Sets Goals for Corporate Social Responsibility Program
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teleflex Incorporated ("Teleflex Incorporated") (NYSE:TFX) concerning possible violations of federal securities laws. On February 27, 2025, Fierce Biotech published an article entitled "Teleflex plays musical chairs, plans company split amid €760M Biotronik cardiovascular deal.